Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab In-licenses Novel EGFR Inhibitor in $233 Million Deal

publication date: Dec 29, 2020

Shanghai's Zai Lab in-licensed China rights to a next-gen EGFR inhibitor aimed at cells expressing mutant EGFR variants from Boston's Cullinan Oncology in an agreement worth up to $233 million. CLN-081 is an oral EGFR inhibitor currently being tested in a US Phase I/IIa trial that enrolled NSCLC patients with EGFR Ex20ins mutations. Zai develops novel targeted oncology and immuno-oncology therapies along with products addressing infectious diseases for China use. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.